title: Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer.
abstract: Human DNA topoisomerases I and IIalpha (Topo-I and -II alpha) are essential for vital cellular processes such as DNA replication, transcription, translation, recombination, and repair. The purpose of this study was to investigate the clinical significance of the expression of Topo-I and Topo-II alpha. Twenty-nine specimens of esophageal squamous cell carcinoma from patients who had been treated by complete resection of the esophageal tumor were studied by an immunohistochemical analysis. High expression of Topo I and II alpha was identified in 48.7% and 55.2% of tumors, respectively. Neither the Topo-I nor -II alpha expression level had any association with clinical characteristics, including differentiation and the depth of tumor invasion, lymph node metastasis, or the patient prognosis. However, a significant positive correlation was observed between the expression levels of Topo-I and Topo-II alpha. Our study results underscore the potential role of topoisomerase expression in esophageal cancer and further exploratory investigation is necessary to evaluate topoisomerase expression as a surrogate marker in chemotherapy with topoisomerase inhibitor for esophageal cancer.
authors.affiliation: Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hanagiri
authors.forename: Kenji
authors.initials: K
authors.lastname: Ono
authors.forename: Taiji
authors.initials: T
authors.lastname: Kuwata
authors.forename: Masaru
authors.initials: M
authors.lastname: Takenaka
authors.forename: Soichi
authors.initials: S
authors.lastname: Oka
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Chikaishi
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Shigematsu
authors.forename: Yoshika
authors.initials: Y
authors.lastname: Nagata
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Shimokawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Nakagawa
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Uramoto
authors.forename: Tomoko
authors.initials: T
authors.lastname: So
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Tanaka
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis*; D015415:Biomarkers / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D002454:Cell Differentiation; D004264:DNA Topoisomerases, Type I / Q000032:analysis*; D004250:DNA Topoisomerases, Type II / Q000032:analysis*; D004268:DNA-Binding Proteins / Q000032:analysis*; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male
chemical_list: D000951:Antigens, Neoplasm; D015415:Biomarkers; D004268:DNA-Binding Proteins; D004264:DNA Topoisomerases, Type I; D004250:DNA Topoisomerases, Type II